Stay updated on SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Sign up to get notified when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.

Latest updates to the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page
- Check6 days agoNo Change Detected
- Check13 days agoChange DetectedThe page's revision label was updated from v3.6.4 to v3.6.5, indicating a new version of the page. This change is a metadata/version update and does not modify the reported study details.SummaryDifference0.0%

- Check20 days agoNo Change Detected
- Check27 days agoChange DetectedRevision label updated from v3.6.3 to v3.6.4 on the page. This reflects a new page version rather than changes to substantive content.SummaryDifference0.0%

- Check48 days agoChange DetectedThe page shows Revision: v3.6.3, replacing the previous Revision: v3.6.1, indicating a newer version reference for an internal document or component on the page.SummaryDifference0.0%

- Check56 days agoChange DetectedThe revision tag on the page has been updated from v3.6.0 to v3.6.1, indicating a minor release label. The content and structure of the page remain the same apart from the version label.SummaryDifference0.0%

- Check64 days agoChange DetectedRecruitment status updated and new study sections added, with a revised Intervention/Treatment area and a version note (v3.6.0).SummaryDifference0.4%

- Check71 days agoChange DetectedThe page revision was updated from v3.5.4 to v3.5.5, indicating a minor update to the page's documentation/versioning. No substantive changes to study information or layout are implied.SummaryDifference0.0%

Stay in the know with updates to SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial
Enter your email address, and we'll notify you when there's something new on the SubQ Risankizumab vs Oral Apremilast in Psoriasis Clinical Trial page.